{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T23:21:09Z","timestamp":1782602469451,"version":"3.54.5"},"reference-count":123,"publisher":"Frontiers Media SA","issue":"4","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":925,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transpl Int"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1111\/tri.12065","type":"journal-article","created":{"date-parts":[[2013,2,19]],"date-time":"2013-02-19T00:37:11Z","timestamp":1361234231000},"page":"358-372","source":"Crossref","is-referenced-by-count":13,"title":["Recurrent hepatitis C virus infection post liver transplantation: impact of choice of calcineurin inhibitor"],"prefix":"10.3389","volume":"26","author":[{"given":"Christophe","family":"Duvoux","sequence":"first","affiliation":[{"name":"Service d'H\u00e9patologie; H\u00f4pital Henri Mondor; Cr\u00e9teil; France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Firpi","sequence":"additional","affiliation":[{"name":"Section of Hepatobiliary Diseases; University of Florida; Gainesville; Florida; USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian L.","family":"Grazi","sequence":"additional","affiliation":[{"name":"UO Chirurgia Epato-Bilio-Pancreatica; Istituto Nazionale dei Tumori Regina Elena; Rome; Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Levy","sequence":"additional","affiliation":[{"name":"University of Toronto Transplant Institute; Toronto General Hospital; Toronto; Ontario; Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eberhard","family":"Renner","sequence":"additional","affiliation":[{"name":"University Health Network\/University of Toronto; Toronto; Ontario; Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Villamil","sequence":"additional","affiliation":[{"name":"Unidad de Transplante Hep\u00e1tico; Hospital Brit\u00e1nico; Buenos Aires; Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2013,2,18]]},"reference":[{"key":"10.1111\/tri.12065-BIB0001|tri12065-cit-0001","unstructured":"US Department of Health & Human Services OPTN\/SRTR 2008 Annual Report. Chapter IV. Liver and intestine transplantation in the United States 1998-2007 http:\/\/optn.transplant.hrsa.gov\/ar2008\/chapter_iv_AR_cd.htm?cp=5"},{"key":"10.1111\/tri.12065-BIB0002|tri12065-cit-0002","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1097\/01.TP.0000129095.51031.42","article-title":"Results of LIS2T, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation","volume":"77","author":"Levy","year":"2004","journal-title":"Transplantation"},{"key":"10.1111\/tri.12065-BIB0003|tri12065-cit-0003","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1002\/lt.20802","article-title":"12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus","volume":"12","author":"Levy","year":"2006","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12065-BIB0004|tri12065-cit-0004","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1111\/j.1600-6143.2011.03508.x","article-title":"Cyclosporine versus tacrolimus treated liver transplant recipients with chronic hepatitis C: outcomes analysis of the UNOS\/OPTN database","volume":"11","author":"Irish","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1111\/tri.12065-BIB0005|tri12065-cit-0005","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1136\/gut.2006.111369","article-title":"Survival after liver transplantation in the United Kingdom and Ireland compared with the United States","volume":"56","author":"Dawwas","year":"2007","journal-title":"Gut"},{"key":"10.1111\/tri.12065-BIB0006|tri12065-cit-0006","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.dld.2010.11.002","article-title":"Liver Match, a prospective observational cohort study on liver transplantation in Italy: study design and current practice of donor-recipient matching","volume":"43","author":"Angelico","year":"2011","journal-title":"Dig Liver Dis"},{"key":"10.1111\/tri.12065-BIB0007|tri12065-cit-0007","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1053\/jhep.2002.31773","article-title":"Hepatitis C virus kinetics during and immediately after liver transplantation","volume":"35","author":"Garcia-Retortillo","year":"2002","journal-title":"Hepatology"},{"key":"10.1111\/tri.12065-BIB0008|tri12065-cit-0008","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/lt.21188","article-title":"Rapidly progressive recurrent hepatitis C virus infection starting 9\u00a0days after liver transplantation","volume":"13","author":"Saraf","year":"2007","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12065-BIB0009|tri12065-cit-0009","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1097\/00007890-199410270-00017","article-title":"Diagnosis of HCV recurrence after liver transplantation using branched DNA assay for HCV RNA quantitation","volume":"58","author":"Duvoux","year":"1994","journal-title":"Transplantation"},{"key":"10.1111\/tri.12065-BIB0010|tri12065-cit-0010","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/S0168-8278(01)00179-9","article-title":"Hepatitis C and liver transplantation","volume":"35","author":"Berenguer","year":"2001","journal-title":"J Hepatol"},{"key":"10.1111\/tri.12065-BIB0011|tri12065-cit-0011","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1002\/lt.21646","article-title":"The natural history of recurrent hepatitis C and what influences this","volume":"14","author":"Gane","year":"2008","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12065-BIB0012|tri12065-cit-0012","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0168-8278(00)80231-7","article-title":"HCV-related fibrosis progression following liver transplantation: increase in recent years","volume":"32","author":"Berenguer","year":"2000","journal-title":"J Hepatol"},{"key":"10.1111\/tri.12065-BIB0013|tri12065-cit-0013","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/lt.21784","article-title":"The natural history of hepatitis C cirrhosis after liver transplantation","volume":"15","author":"Firpi","year":"2009","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12065-BIB0014|tri12065-cit-0014","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1053\/gast.2002.32418","article-title":"The association between hepatitis C infection and survival after orthotopic liver transplantation","volume":"122","author":"Forman","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1111\/tri.12065-BIB0015|tri12065-cit-0015","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1053\/jhep.2002.33993","article-title":"Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients","volume":"36","author":"Berenguer","year":"2002","journal-title":"Hepatology"},{"key":"10.1111\/tri.12065-BIB0016|tri12065-cit-0016","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1053\/jhep.2000.19340","article-title":"Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation","volume":"32","author":"Sreekumar","year":"2000","journal-title":"Hepatology"},{"key":"10.1111\/tri.12065-BIB0017|tri12065-cit-0017","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1002\/lt.20238","article-title":"One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection","volume":"10","author":"Firpi","year":"2004","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12065-BIB0018|tri12065-cit-0018","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/jlts.2003.50268","article-title":"Report of the first International Liver Transplantation Society Expert Panel consensus conference on liver transplantation and hepatitis C","volume":"9","author":"Wiesner","year":"2003","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12065-BIB0019|tri12065-cit-0019","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1111\/j.1600-6143.2006.01408.x","article-title":"The impact of diabetes mellitus on fibrosis progression in patients transplanted for hepatitis C","volume":"6","author":"Foxton","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1111\/tri.12065-BIB0020|tri12065-cit-0020","doi-asserted-by":"crossref","first-page":"S116","DOI":"10.1111\/j.1600-6143.2009.02902.x","article-title":"Viral hepatitis in solid organ transplant recipients","volume":"9","author":"Levitsky","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1111\/tri.12065-BIB0021|tri12065-cit-0021","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1002\/lt.21954","article-title":"Natural history of post-liver transplantation hepatitis C: A review of factors that may influence its course","volume":"15","author":"Gallegos-Orozco","year":"2009","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12065-BIB0022|tri12065-cit-0022","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1111\/j.1600-6143.2009.02702.x","article-title":"A practical guide to the management of HCV infection following liver transplantation","volume":"9","author":"Watt","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1111\/tri.12065-BIB0023|tri12065-cit-0023","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"Diagnosis, management, and treatment of hepatitis C: an update","volume":"49","author":"Ghany","year":"2009","journal-title":"Hepatology"},{"key":"10.1111\/tri.12065-BIB0024|tri12065-cit-0024","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1055\/s-0029-1192055","article-title":"Hepatitis C","volume":"29","author":"Burra","year":"2009","journal-title":"Semin Liver Dis"},{"key":"10.1111\/tri.12065-BIB0025|tri12065-cit-0025","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1097\/TP.0b013e3181bd783c","article-title":"Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome","volume":"88","author":"Selzner","year":"2009","journal-title":"Transplantation"},{"key":"10.1111\/tri.12065-BIB0026|tri12065-cit-0026","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jhep.2006.10.017","article-title":"Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation","volume":"46","author":"Picciotto","year":"2007","journal-title":"J Hepatol"},{"key":"10.1111\/tri.12065-BIB0027|tri12065-cit-0027","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jhep.2008.05.002","article-title":"Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin","volume":"49","author":"Berenguer","year":"2008","journal-title":"J Hepatol"},{"key":"10.1111\/tri.12065-BIB0028|tri12065-cit-0028","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1053\/jlts.2002.34968","article-title":"Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C","volume":"8","author":"Firpi","year":"2002","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12065-BIB0029|tri12065-cit-0029","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"Bacon","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1111\/tri.12065-BIB0030|tri12065-cit-0030","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa0807650","article-title":"Telaprevir and peginterferon with or without ribavirin for chronic HCV infection","volume":"360","author":"H\u00e9zode","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1111\/tri.12065-BIB0031|tri12065-cit-0031","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1056\/NEJMoa0806104","article-title":"Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection","volume":"360","author":"McHutchison","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1111\/tri.12065-BIB0032|tri12065-cit-0032","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/S0168-8278(12)60061-0","article-title":"Efficacy and safety of protease inhibitors for severe hepatitis C recurrence after liver transplantation: a first multicentric experience","volume":"56","author":"Coilly","year":"2012","journal-title":"J Hepatol"},{"key":"10.1111\/tri.12065-BIB0033|tri12065-cit-0033","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1111\/j.1600-6143.2006.01360.x","article-title":"Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis","volume":"6","author":"McAlister","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1111\/tri.12065-BIB0034|tri12065-cit-0034","first-page":"Art No. CD00516","article-title":"Cyclosporin versus tacrolimus for liver transplanted patients","author":"Haddad","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/tri.12065-BIB0035|tri12065-cit-0035","first-page":"2977","article-title":"A randomized trial of primary liver transplantation under immunosuppression with FK 506 versus cyclosporine","volume":"23","author":"Fung","year":"1991","journal-title":"Transplant Proc"},{"key":"10.1111\/tri.12065-BIB0036|tri12065-cit-0036","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1111\/j.1432-2277.1994.tb01306.x","article-title":"Patient and graft survival in the European Multicentre Liver Study - FK 506 vs cyclosporin A","volume":"7","author":"McMaster","year":"1994","journal-title":"Transpl Int"},{"key":"10.1111\/tri.12065-BIB0037|tri12065-cit-0037","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0140-6736(94)91766-3","article-title":"Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection","volume":"344","author":"European FK506 Multicentre Liver Study Group","year":"1994","journal-title":"Lancet"},{"key":"10.1111\/tri.12065-BIB0038|tri12065-cit-0038","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1097\/TP.0b013e3181fa93fa","article-title":"Effect of calcineurin inhibitors in the outcome of liver transplantation in hepatitis C virus-positive recipients","volume":"90","author":"Berenguer","year":"2010","journal-title":"Transplantation"},{"key":"10.1111\/tri.12065-BIB0039|tri12065-cit-0039","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1600-6143.2006.01576.x","article-title":"Randomized controlled trial of tacrolimus versus microemulsified cyclosporin (TMC) in liver transplantation: poststudy surveillance to 3\u00a0years","volume":"7","author":"O'Grady","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1111\/tri.12065-BIB0040|tri12065-cit-0040","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/lt.21035","article-title":"Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis","volume":"13","author":"Berenguer","year":"2007","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12065-BIB0041|tri12065-cit-0041","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1053\/jhep.2003.50449","article-title":"Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes","volume":"38","author":"Watashi","year":"2003","journal-title":"Hepatology"},{"key":"10.1111\/tri.12065-BIB0042|tri12065-cit-0042","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.bbrc.2003.11.080","article-title":"Specific inhibition of hepatitis C virus replication by cyclosporin A","volume":"313","author":"Nakagawa","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1111\/tri.12065-BIB0043|tri12065-cit-0043","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/lt.20532","article-title":"Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation","volume":"12","author":"Firpi","year":"2006","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12065-BIB0044|tri12065-cit-0044","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.bbrc.2006.03.059","article-title":"Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811","volume":"343","author":"Goto","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1111\/tri.12065-BIB0045|tri12065-cit-0045","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.4049\/jimmunol.143.5.1580","article-title":"FK-506, a potent novel immunosuppressive agent, binds to a cytosolic protein which is distinct from the cyclosporin A-binding protein, cyclophilin","volume":"143","author":"Siekierka","year":"1989","journal-title":"J Immunol"},{"key":"10.1111\/tri.12065-BIB0046|tri12065-cit-0046","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/rmv.534","article-title":"Chemical genetics approach to hepatitis C virus replication: cyclophilin as a target for anti-hepatitis C virus strategy","volume":"17","author":"Watashi","year":"2007","journal-title":"Rev Med Virol"},{"key":"10.1111\/tri.12065-BIB0047|tri12065-cit-0047","doi-asserted-by":"crossref","first-page":"e1001118","DOI":"10.1371\/journal.ppat.1001118","article-title":"A major determinant of cyclophilin dependence and cyclosporine susceptibility of hepatitis C virus identified by a genetic approach","volume":"6","author":"Yang","year":"2010","journal-title":"PLoS Pathog"},{"key":"10.1111\/tri.12065-BIB0048|tri12065-cit-0048","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.cld.2009.05.002","article-title":"Cyclophilin inhibitors","volume":"13","author":"Gallay","year":"2009","journal-title":"Clin Liver Dis"},{"key":"10.1111\/tri.12065-BIB0049|tri12065-cit-0049","doi-asserted-by":"crossref","unstructured":"Flisiak R Pawlotsky J-M Crabb\u00e9 R et\u00a0al Once daily alisporivir (Deb025) plus PegIFNalpha2a\/ribavirin results in superior sustained virologic response (SVR24) in chronic hepatitis C genotype 1 treatment na\u00efve patients","DOI":"10.1016\/S0168-8278(11)60006-8"},{"key":"10.1111\/tri.12065-BIB0050|tri12065-cit-0050","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/lt.22400","article-title":"Impact of calcineurin inhibitors with or without interferon on hepatitis C virus titers in a chimeric mouse model of hepatitis C virus infection","volume":"18","author":"Kneteman","year":"2012","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12065-BIB0051|tri12065-cit-0051","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1002\/lt.20222","article-title":"Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: a prospective, randomized trial","volume":"10","author":"Martin","year":"2004","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12065-BIB0052|tri12065-cit-0052","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/lt.20655","article-title":"Effect of calcineurin inhibitors on survival and histologic disease severity in HCV-infected liver transplant recipients","volume":"12","author":"Berenguer","year":"2006","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12065-BIB0053|tri12065-cit-0053","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s10620-011-1871-z","article-title":"Impact of calcineurin inhibitors on hepatitis C recurrence after liver transplantation","volume":"57","author":"Kim","year":"2012","journal-title":"Dig Dis Sci"},{"key":"10.1111\/tri.12065-BIB0054|tri12065-cit-0054","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1053\/j.gastro.2007.03.041","article-title":"Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study","volume":"132","author":"Carri\u00f3n","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1111\/tri.12065-BIB0055|tri12065-cit-0055","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1002\/lt.20883","article-title":"Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation","volume":"12","author":"Fern\u00e1ndez","year":"2006","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12065-BIB0056|tri12065-cit-0056","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/lt.21707","article-title":"Worse recent efficacy of antiviral therapy in liver transplant recipients with recurrent hepatitis C: impact of donor age and baseline cirrhosis","volume":"15","author":"Berenguer","year":"2009","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12065-BIB0057|tri12065-cit-0057","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00535-002-1104-5","article-title":"Combined interferon \u03b12b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial","volume":"38","author":"Inoue","year":"2003","journal-title":"J Gastroenterol"},{"key":"10.1111\/tri.12065-BIB0058|tri12065-cit-0058","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/TP.0b013e318223d836","article-title":"Cyclosporine A-based immunosuppression reduces relapse rate after antiviral therapy in transplanted patients with hepatitis C virus infection: a large multicenter cohort study","volume":"92","author":"ReViS-TC Study Group","year":"2011","journal-title":"Transplantation"},{"key":"10.1111\/tri.12065-BIB0059|tri12065-cit-0059","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/lt.23516","article-title":"Efficacy of antiviral therapy for hepatitis C after liver transplantation with cyclosporine and tacrolimus: A systematic review and meta-analysis","volume":"19","author":"Rabie","year":"2013","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12065-BIB0060|tri12065-cit-0060","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/lt.21760","article-title":"Predictors of sustained virological response after antiviral treatment for hepatitis C recurrence following liver transplantation","volume":"15","author":"Cescon","year":"2009","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12065-BIB0061|tri12065-cit-0061","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1016\/j.transproceed.2006.10.040","article-title":"A cyclosporine-based immunosuppressive regimen may be better than tacrolimus for long-term liver allograft survival in recipients transplanted for hepatitis C","volume":"38","author":"Rayhill","year":"2006","journal-title":"Transplant Proc"},{"key":"10.1111\/tri.12065-BIB0062|tri12065-cit-0062","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1002\/lt.20737","article-title":"Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C","volume":"12","author":"Berenguer","year":"2006","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12065-BIB0063|tri12065-cit-0063","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s10620-009-0981-3","article-title":"The use of cyclosporine for recurrent hepatitis C after liver transplant: a randomized pilot study","volume":"55","author":"Firpi","year":"2010","journal-title":"Dig Dis Sci"},{"key":"10.1111\/tri.12065-BIB0064|tri12065-cit-0064","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/j.1365-2036.2008.03761.x","article-title":"Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation","volume":"28","author":"Lodato","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/tri.12065-BIB0065|tri12065-cit-0065","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/lt.21312","article-title":"Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon\/ribavirin therapy","volume":"14","author":"Hanouneh","year":"2008","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12065-BIB0066|tri12065-cit-0066","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jhep.2003.12.015","article-title":"Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination","volume":"40","author":"Dumortier","year":"2004","journal-title":"J Hepatol"},{"key":"10.1111\/tri.12065-BIB0067|tri12065-cit-0067","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1111\/j.1600-6143.2006.01470.x","article-title":"Hepatitis C recurrence after liver transplantation: viral and histologic response to full-dose Peg-interferon and ribavirin","volume":"6","author":"Oton","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1111\/tri.12065-BIB0068|tri12065-cit-0068","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/S0168-8278(12)60099-3","article-title":"Interaction between cyclosporine and recipient il-28b rs12979860 c\u00a0>\u00a0t genetic polymorphisms in the achievement of sustained viral response for recurrent hepatitis C","volume":"56","author":"Bitetto","year":"2012","journal-title":"J Hepatol"},{"key":"10.1111\/tri.12065-BIB0069|tri12065-cit-0069","first-page":"189A","article-title":"Multicenter randomized trial in HCV-infected patients treated with peginterferon alfa-2a and ribavirin followed by ribavirin alone after liver transplantation: 18-month report","volume":"44","author":"Calmus","year":"2010","journal-title":"Hepatology"},{"key":"10.1111\/tri.12065-BIB0070|tri12065-cit-0070","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1002\/lt.22387","article-title":"Anemia is not predictive of sustained virological response in liver transplant recipients with hepatitis C virus who are treated with pegylated interferon and ribavirin","volume":"17","author":"Giusto","year":"2011","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12065-BIB0071|tri12065-cit-0071","first-page":"754A","article-title":"Baseline, donor, and on-treatment predictors of sustained virologic response in patients treated for recurrent hepatitis C following orthotopic liver transplant: subanalysis of the PROTECT study","volume":"52","author":"Gordon","year":"2010","journal-title":"Hepatology"},{"key":"10.1111\/tri.12065-BIB0072|tri12065-cit-0072","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1016\/j.transproceed.2009.08.070","article-title":"The benefits of interferon treatment in patients without sustained viral response after living donor liver transplantation for hepatitis C","volume":"41","author":"Ikegami","year":"2009","journal-title":"Transplant Proc"},{"key":"10.1111\/tri.12065-BIB0073|tri12065-cit-0073","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.transproceed.2010.02.008","article-title":"Hepatitis C virus recurrence after liver transplantation: analysis of factors related to sustained viral response","volume":"42","author":"Jim\u00e9nez-P\u00e9rez","year":"2010","journal-title":"Transplant Proc"},{"key":"10.1111\/tri.12065-BIB0074|tri12065-cit-0074","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1002\/lt.21635","article-title":"Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis","volume":"14","author":"Roche","year":"2008","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12065-BIB0075|tri12065-cit-0075","first-page":"S97","article-title":"Is the primary immunosuppressive drug (cyclosporine or tacrolimus) playing a role on the response to antiviral treatment for post-transplant HCV-recurrence?","volume":"17","author":"Vero","year":"2011","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12065-BIB0076|tri12065-cit-0076","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/01.tp.0000229397.81425.51","article-title":"Cyclosporin A for treatment of hepatitis C virus after liver transplantation [letter]","volume":"82","author":"Sugawara","year":"2006","journal-title":"Transplantation"},{"key":"10.1111\/tri.12065-BIB0077|tri12065-cit-0077","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/hep.24074","article-title":"Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection","volume":"53","author":"Charlton","year":"2011","journal-title":"Hepatology"},{"key":"10.1111\/tri.12065-BIB0078|tri12065-cit-0078","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1053\/jlts.2002.31655","article-title":"Intrahepatic cytokine profiles associated with posttransplantation hepatitis C virus-related liver injury","volume":"8","author":"Zekry","year":"2002","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12065-BIB0079|tri12065-cit-0079","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1097\/01.tp.0000258729.68871.be","article-title":"Elevated interleukin-4 expression in severe recurrent hepatitis C virus after liver transplantation","volume":"83","author":"Dharancy","year":"2007","journal-title":"Transplantation"},{"key":"10.1111\/tri.12065-BIB0080|tri12065-cit-0080","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S0168-8278(99)80150-0","article-title":"Increased expression of interleukin-4 during liver allograft rejection","volume":"30","author":"Conti","year":"1999","journal-title":"J Hepatol"},{"key":"10.1111\/tri.12065-BIB0081|tri12065-cit-0081","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/labinvest.2008.61","article-title":"Interleukin-4 induces the activation and collagen production of cultured human intrahepatic fibroblasts via the STAT-6 pathway","volume":"88","author":"Aoudjehane","year":"2008","journal-title":"Lab Invest"},{"key":"10.1111\/tri.12065-BIB0082|tri12065-cit-0082","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1002\/hep.1840210440","article-title":"Cyclosporin A and FK-506 in inhibition of rat Ito cell activation in vitro","volume":"21","author":"Ikeda","year":"1995","journal-title":"Hepatology"},{"key":"10.1111\/tri.12065-BIB0083|tri12065-cit-0083","doi-asserted-by":"crossref","first-page":"4598","DOI":"10.1016\/j.transproceed.2005.10.104","article-title":"Cyclosporine suppresses cell growth and collagen production in hepatic stellate cells","volume":"37","author":"Nakamuta","year":"2005","journal-title":"Transplant Proc"},{"key":"10.1111\/tri.12065-BIB0084|tri12065-cit-0084","doi-asserted-by":"crossref","first-page":"4343","DOI":"10.1016\/j.transproceed.2010.09.124","article-title":"Cyclosporine inhibits profibrotic effects of interleukin-4 and transforming growth factor \u03b2 on human intrahepatic fibroblasts cultured in vitro","volume":"42","author":"Pissaia","year":"2010","journal-title":"Transplant Proc"},{"key":"10.1111\/tri.12065-BIB0085|tri12065-cit-0085","first-page":"1075","article-title":"Liver fibrosis: a dynamic and potentially reversible process","volume":"25","author":"Povero","year":"2010","journal-title":"Histol Histopathol"},{"key":"10.1111\/tri.12065-BIB0086|tri12065-cit-0086","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1097\/00007890-199904150-00027","article-title":"Apoptosis and the expression of Fas and Fas ligand (FasL) antigen in rejection and reinfection in liver allograft specimens","volume":"67","author":"Tannapfel","year":"1999","journal-title":"Transplantation"},{"key":"10.1111\/tri.12065-BIB0087|tri12065-cit-0087","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/hep.20411","article-title":"Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury","volume":"40","author":"Bantel","year":"2004","journal-title":"Hepatology"},{"key":"10.1111\/tri.12065-BIB0088|tri12065-cit-0088","doi-asserted-by":"crossref","first-page":"7826","DOI":"10.1016\/S0021-9258(18)83116-7","article-title":"Cyclosporin A is a potent inhibitor of the inner membrane permeability transition in liver mitochondria","volume":"264","author":"Broekemeier","year":"1989","journal-title":"J Biol Chem"},{"key":"10.1111\/tri.12065-BIB0089|tri12065-cit-0089","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1053\/gast.2003.50059","article-title":"Mitochondrial permeability transition in the switch from necrotic to apoptotic cell death in ischemic rat hepatocytes","volume":"124","author":"Kim","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1111\/tri.12065-BIB0090|tri12065-cit-0090","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1254\/jjp.79.485","article-title":"The protective effect of cyclosporine A on anti-Fas antibody-induced hepatitis in mice","volume":"79","author":"Okamoto","year":"1999","journal-title":"Jpn J Pharmacol"},{"key":"10.1111\/tri.12065-BIB0091|tri12065-cit-0091","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jss.2009.06.054","article-title":"Diverse effects of FK506 on the apoptosis of hepatocytes and infiltrating lymphocytes in an allografted rat liver","volume":"167","author":"Moriuchi","year":"2011","journal-title":"J Surg Res"},{"key":"10.1111\/tri.12065-BIB0092|tri12065-cit-0092","unstructured":"Duvoux C Mennecier D Pageaux GP Conti F Roudot-Thoraval F Dhumeaux D Immunosuppression with tacrolimus and absence of antihypertensive therapy are associated with fibrosis progression after hepatitis C virus (HCV) graft reinfection"},{"key":"10.1111\/tri.12065-BIB0093|tri12065-cit-0093","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1016\/j.transproceed.2006.08.131","article-title":"Long-term outcomes in liver transplant patients with hepatic C infection receiving tacrolimus or cyclosporine","volume":"38","author":"Villamil","year":"2006","journal-title":"Transplant Proc"},{"key":"10.1111\/tri.12065-BIB0094|tri12065-cit-0094","first-page":"S152","article-title":"The effect of calcineurin inhibitor usage on hepatic fibrosis progression in HCV-positive liver transplant recipients: a two-centre study","volume":"13","author":"Laan","year":"2007","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12065-BIB0095|tri12065-cit-0095","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/lt.21178","article-title":"Hepatic stellate cell activation in liver transplant patients with hepatitis C recurrence and in non-transplanted patients with chronic hepatitis C","volume":"13","author":"Cisneros","year":"2007","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12065-BIB0096|tri12065-cit-0096","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1080\/08998280.2011.11928712","article-title":"Effect of tacrolimus on survival in hepatitis C-infected patients after liver transplantation","volume":"24","author":"O'Leary","year":"2011","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"10.1111\/tri.12065-BIB0097|tri12065-cit-0097","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/j.transproceed.2005.02.103","article-title":"Retrospective analysis of the impact of immunosuppression on the course of recurrent hepatitis C after liver transplantation","volume":"37","author":"Bahr","year":"2005","journal-title":"Transplant Proc"},{"key":"10.1111\/tri.12065-BIB0098|tri12065-cit-0098","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1053\/jlts.2001.27803","article-title":"Histological recurrence and progression of hepatitis C after orthotopic liver transplantation: influence of immunosuppressive regimens","volume":"7","author":"Hunt","year":"2001","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12065-BIB0099|tri12065-cit-0099","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.1016\/j.transproceed.2010.10.013","article-title":"Results of a two-center study comparing hepatic fibrosis progression in HCV-positive liver transplant patients receiving cyclosporine or tacrolimus","volume":"42","author":"Laan","year":"2010","journal-title":"Transplant Proc"},{"key":"10.1111\/tri.12065-BIB0100|tri12065-cit-0100","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1001\/archsurg.1996.01430150062013","article-title":"Hepatitis C viral infection in liver transplantation","volume":"131","author":"Johnson","year":"1996","journal-title":"Arch Surg"},{"key":"10.1111\/tri.12065-BIB0101|tri12065-cit-0101","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1016\/j.transproceed.2006.08.055","article-title":"Hepatitis C virus recurrence after liver transplantation: influence of immunosuppressive regimens on viral load and liver histology","volume":"38","author":"Oton","year":"2006","journal-title":"Transplant Proc"},{"key":"10.1111\/tri.12065-BIB0102|tri12065-cit-0102","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.transproceed.2011.02.034","article-title":"Successful treatment of fibrosing cholestatic hepatitis after liver transplantation","volume":"43","author":"Cimsit","year":"2011","journal-title":"Transplant Proc"},{"key":"10.1111\/tri.12065-BIB0103|tri12065-cit-0103","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.jhep.2008.08.006","article-title":"Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis","volume":"49","author":"White","year":"2008","journal-title":"J Hepatol"},{"key":"10.1111\/tri.12065-BIB0104|tri12065-cit-0104","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/lt.21010","article-title":"Risk factors for new-onset diabetes mellitus following liver transplantation and impact of hepatitis C infection: an observational multicenter study","volume":"13","author":"Saliba","year":"2007","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12065-BIB0105|tri12065-cit-0105","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1002\/lt.21524","article-title":"The significance of metabolic syndrome in the setting of recurrent hepatitis C after liver transplantation","volume":"14","author":"Hanouneh","year":"2008","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12065-BIB0106|tri12065-cit-0106","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1111\/j.1600-6143.2009.02642.x","article-title":"Insulin resistance, serum adipokines and risk of fibrosis progression in patients transplanted for hepatitis C","volume":"9","author":"Veldt","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1111\/tri.12065-BIB0107|tri12065-cit-0107","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1053\/j.gastro.2004.12.049","article-title":"Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients","volume":"128","author":"Romero-G\u00f3mez","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1111\/tri.12065-BIB0108|tri12065-cit-0108","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1007\/s10620-008-0683-2","article-title":"Diabetes mellitus is associated with impaired response to antiviral therapy in chronic hepatitis C infection","volume":"54","author":"Elgouhari","year":"2009","journal-title":"Dig Dis Sci"},{"key":"10.1111\/tri.12065-BIB0109|tri12065-cit-0109","first-page":"581A","article-title":"Early virological response and absence of diabetes are associated with sustained virological response to hepatitis C treatment after liver transplantation in patients with cyclosporine A based immunosuppression","volume":"48","author":"Hurtova","year":"2008","journal-title":"Hepatology"},{"key":"10.1111\/tri.12065-BIB0110|tri12065-cit-0110","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/lt.20634","article-title":"Conversion from tacrolimus to cyclosporine in liver transplanted patients with diabetes mellitus","volume":"12","author":"Dumortier","year":"2006","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12065-BIB0111|tri12065-cit-0111","first-page":"328","article-title":"Conversion to cyclosporine therapy induces significant benefits in liver transplant recipients on tacrolimus with new onset diabetes: the DIALIVER study","volume":"9","author":"Rendina","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1111\/tri.12065-BIB0112|tri12065-cit-0112","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1016\/j.transproceed.2008.08.116","article-title":"Influence of immunosuppression and effect of hepatitis C virus on new onset of diabetes mellitus in liver transplant recipients","volume":"40","author":"S\u00e1nchez-P\u00e9rez","year":"2008","journal-title":"Transplant Proc"},{"key":"10.1111\/tri.12065-BIB0113|tri12065-cit-0113","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/lt.20708","article-title":"Natural killer cells: primary target for hepatitis C virus immune evasion strategies?","volume":"12","author":"Golden-Mason","year":"2006","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12065-BIB0114|tri12065-cit-0114","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/S0016-5085(99)70352-5","article-title":"Association of multispecific CD4+ response to hepatitis C and severity of recurrence after liver transplantation","volume":"117","author":"Rosen","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1111\/tri.12065-BIB0115|tri12065-cit-0115","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/lt.21265","article-title":"Pretransplantation CD56+ innate lymphocyte populations associated with severity of hepatitis C virus recurrence","volume":"14","author":"Rosen","year":"2008","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12065-BIB0116|tri12065-cit-0116","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.transproceed.2004.12.293","article-title":"HCV core protein augments cyclosporine immunosuppression","volume":"37","author":"Kimball","year":"2005","journal-title":"Transplant Proc"},{"key":"10.1111\/tri.12065-BIB0117|tri12065-cit-0117","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1002\/hep.20454","article-title":"An immunomodulatory role for CD4+CD25+ regulatory T lymphocytes in hepatitis C virus infection","volume":"40","author":"Cabrera","year":"2004","journal-title":"Hepatology"},{"key":"10.1111\/tri.12065-BIB0118|tri12065-cit-0118","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1016\/j.transproceed.2009.08.043","article-title":"Inhibitory effects of cyclosporine on human regulatory T cells in vitro","volume":"41","author":"Miroux","year":"2009","journal-title":"Transplant Proc"},{"key":"10.1111\/tri.12065-BIB0119|tri12065-cit-0119","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1365-2249.2010.04183.x","article-title":"The calcineurin inhibitor tacrolimus allows the induction of functional CD4+ CD25+ regulatory T cells by rabbit anti-thymocyte globulins","volume":"161","author":"Sewgobind","year":"2010","journal-title":"Clin Exp Immunol"},{"key":"10.1111\/tri.12065-BIB0120|tri12065-cit-0120","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/j.1432-2277.2005.00151.x","article-title":"Use of Neoral C2 monitoring: a European consensus","volume":"18","author":"Nashan","year":"2005","journal-title":"Transpl Int"},{"key":"10.1111\/tri.12065-BIB0121|tri12065-cit-0121","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1053\/jlts.2000.9741","article-title":"Liver transplantation for hepatitis C: recurrence and disease progression in 300 patients","volume":"6","author":"Testa","year":"2000","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12065-BIB0122|tri12065-cit-0122","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/hep.1840210107","article-title":"Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation","volume":"21","author":"Sheiner","year":"1995","journal-title":"Hepatology"},{"key":"10.1111\/tri.12065-BIB0123|tri12065-cit-0123","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S0041-1345(03)00009-5","article-title":"Comparison of tacrolimus with cyclosporin as primary immunosuppression in patients with hepatitis C virus infection after liver transplantation","volume":"35","author":"Ben-Ari","year":"2003","journal-title":"Transplant Proc"}],"container-title":["Transplant International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftri.12065","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/tri.12065\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T21:34:26Z","timestamp":1745962466000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tri.12065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,18]]},"references-count":123,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,4]]}},"URL":"https:\/\/doi.org\/10.1111\/tri.12065","relation":{},"ISSN":["0934-0874"],"issn-type":[{"value":"0934-0874","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2,18]]}}}